Remission (≤3) | Low (3.1–6) | Moderate (6.1–12) | High (>12) | |
---|---|---|---|---|
Site 1 (N=137) | 32 (23.4%) | 11 (8%) | 31 (22.6%) | 63 (46%) |
Female, n (%) | 27 (84.4%) | 9 (81.8%) | 26 (83.9%) | 59 (93.6%) |
Age, yrs | 58.5 (16.9) | 57.9 (18.8) | 56.8 (17.5) | 55.6 (14.5) |
Fatigue (0–10) | 1.1 (1.5) | 2.3 (2.0) | 3.1 (2.1) | 6.6 (2.3)* |
Self-report RADAI (0–48) | 1.9 (2.9) | 5.0 (3.9) | 7.5 (5.60 | 17.0 (9.2)* |
DOCGL (0–10) | 1.6 (1.2) | 3.7 (1.7) | 3.2 (1.4) | 5.3 (1.9)* |
Site 2 (N=144) | 37 (25.7%) | 35 (24.3%) | 42 (29.2%) | 30 (20.8%) |
Female, n (%) | 28 (75.7%) | 22 (62.9%) | 34 (80.9%) | 24 (80%) |
Age, yrs | 56.6 (16.9) | 62.0 (14.6) | 62.3 (14.7) | 62.5 (15.9) |
Fatigue (0–10) | 0.9 (1.0) | 2.7 (1.9) | 4.1 (2.4) | 5.6 (3.0)* |
Self-report RADAI (0–48) | NA | NA | NA | NA |
DOCGL (0–10) | 0.9 (1.3) | 1.0 (1.0) | 1.7 (1.5) | 3.4 (2.7)* |
Site 3 (N=139) | 32 (23%) | 10 (7%) | 33 (23.7%) | 64 (46%) |
Female, n (%) | 23 (72%) | 9 (90%) | 20 (62%) | 50 (79%) |
Age, yrs | 44.4 (13.8) | 43.8 (17.0) | 50.3 (17.8) | 50.9 (15.0) |
Fatigue (0–10) | 0.4 (0.8) | 2.6 (2.7) | 4.1 (2.7) | 6.9 (2.9)* |
Self-report RADAI (0–48) | 1.3 (1.9) | 4.7 (4.2) | 5.7 (5.1) | 18.3 (12.2)* |
DOCGL (0–10) | 1.1 (1.1) | 3.2 (1.9) | 2.5 (1.2) | 3.2 (1.5)* |